BPTS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

Stats
Today's Volume	338 907
Average Volume	338 411
Market Cap	3.75M
EPS	€0 ( 2024-04-16 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.100
ATR14	€0.00600 (1.84%)

Volume Correlation

Long: 0.04 (neutral)

Short: -0.77 (moderate negative)

Signal:(42.731) Neutral

Biophytis SA American Correlation

10 Most Positive Correlations
SERA	0.952
BAOS	0.934
LEXX	0.932
PBHC	0.924
OPOF	0.922
WNEB	0.913
PEBK	0.911
HWBK	0.911
CBFV	0.909
QNST	0.908

10 Most Negative Correlations
ENNVU	-0.975
ENVI	-0.954
GOODM	-0.901
MSFT	-0.899
GXII	-0.898
ISRG	-0.898
AQST	-0.897
BLRX	-0.897
APEI	-0.896
ISEE	-0.896

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Biophytis SA American Correlation - Currency/Commodity

-0.54
( weak negative )

-0.76
( moderate negative )

0.00
( neutral )

-0.64
( weak negative )

0.00
( neutral )

0.86
( strong )

Biophytis SA American Financials

Annual	2023
Revenue:	€0
Gross Profit:	€-803 000 (0.00 %)
EPS:	€-0.0314

Q4	2023
Revenue:	€0
Gross Profit:	€-653 000 (0.00 %)
EPS:	€-0.00890

Q2	2023
Revenue:	€0
Gross Profit:	€-150 000 (0.00 %)
EPS:	€-0.0237

Q4	2022
Revenue:	€0
Gross Profit:	€-334 000 (0.00 %)
EPS:	€-0.0546

Financial Reports:

No articles found.

Biophytis SA American

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.